Drug Interactions between Caltro with Vitamin D and futibatinib
This report displays the potential drug interactions for the following 2 drugs:
- Caltro with Vitamin D (calcium/vitamin d)
- futibatinib
Interactions between your drugs
ergocalciferol futibatinib
Applies to: Caltro with Vitamin D (calcium / vitamin d) and futibatinib
Consumer information for this interaction is not currently available.
MONITOR: Coadministration of agents that can increase serum phosphate levels during treatment with fibroblast growth factor receptor (FGFR) inhibitors may lead to elevated serum phosphate levels. The mechanism appears to be related to the pharmacodynamic effects of FGFR inhibition, which has been shown to lead to an increase in serum phosphate levels, including hyperphosphatemia. Hyperphosphatemia can cause precipitation of calcium-phosphate crystals which over time can lead to hypocalcemia, soft tissue mineralization such as cutaneous calcification and calcinosis, secondary hyperparathyroidism, anemia, muscle cramps, seizures, QT prolongation, and arrhythmias. Soft tissue mineralization, including cutaneous calcification, calcinosis, and non-uremic calciphylaxis have been observed during treatment with other FGFR inhibitors.
MANAGEMENT: Close monitoring of serum phosphate levels is recommended throughout treatment with FGFR inhibitors, including futibatinib and pemigatinib, particularly at the start of therapy and if used concomitantly with agents that may increase serum phosphate levels. Agents that may increase serum phosphate levels include potassium phosphate supplements, vitamin D supplements, antacids, phosphate-containing enemas or laxatives, and medications known to have phosphate as an excipient. In the event of hyperphosphatemia, dose adjustment of the FGFR inhibitor, use of phosphate-lowering therapy, dietary phosphate restriction, and/or temporary or permanent cessation of the FGFR inhibitor may be required, depending on the duration and severity of the hyperphosphatemia. The manufacturer's product labeling should be consulted for further information and dosage adjustment guidance.
References
- "Product Information. Balversa (erdafitinib)." Janssen Products, LP (2019):
- "Product Information. Pemazyre (pemigatinib)." Incyte Corporation (2020):
- "Product Information. Lytgobi (futibatinib)." Taiho Oncology, Inc. 1 (2022):
- "Product Information. Pemazyre (pemigatinib)." Specialised Therapeutics Alim Pty Ltd (2022):
- "Product Information. Pemazyre (pemigatinib)." Incyte Biosciences UK Ltd (2023):
Drug and food interactions
futibatinib food
Applies to: futibatinib
Grapefruit juice can increase the blood levels of futibatinib. This may increase side effects including dry or inflamed eyes, inflamed cornea, increased tears, disorder of the retina, high phosphate levels in your blood, redness, swelling, peeling or tenderness, mainly on the hands or feet, nails separating from the bed or poor formation of the nail, urinary tract infection, constipation, diarrhea, dry mouth, abdominal pain, fatigue, muscle and joint pain, decreased levels of blood cells (white blood cells, red blood cells, and platelets), and changes in liver function blood tests. You should avoid the consumption of grapefruit and grapefruit juice during treatment with futibatinib. Be sure to take the medication at approximately the same time every day to maintain consistent blood levels and effects. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
calcium carbonate food
Applies to: Caltro with Vitamin D (calcium / vitamin d)
Calcium absorption may be increased by taking it with food. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption. Calcium may be taken with food to increase absorption. Consider spacing calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.